



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 3

<b>Application Number</b>	09/887,465
<b>Filing Date</b>	June 22, 2001
<b>First Named Inventor</b>	Edward B. Nelson et al.
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	MCP-267

TECH CENTER 1800/2800

JAN 8 2002


RECEIVED

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature		Date Considered	12/2/82
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TECH CENTER 15002900

JAN 07 2002

RECEIVED

Substitute for Form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(use as many sheets as necessary)  
Sheet 2 of 3

Application Number	09/887,465
Filing Date	June 22, 2001
First Named Inventor	Edward B. Nelson et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	MCP-267

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
G		"Effect of Acetaminophen on Myeloperoxidase-Nitrite Mediated Oxidation of LDL", Chou, Tien-min et al., American Heart Association, First conference on arteriosclerosis, Thrombosis, and Vascular Biology, May 20-22, 2000, Omni Interlocken Broomfield/Denver, Colorado (Abstract)	
G		"Acetaminophen Inhibits Fatty Streak Formation and LDL Oxysterols in Hypercholesterolemic Rabbits", Addison A. Taylor et al., Abstracts From the 72 <sup>nd</sup> Scientific Sessions, Circulation, Vol. 100, Supp. 18, 2 Nov. 1999, p. I-697, Abstract No. 3677	
G		"Acetaminophen blocks atherosclerosis enzyme", C.F. Bergmann, Cardiology Today, July 2000	
G		"A New Screening Method to Detect Water-soluble Antioxidants: Acetaminophen (Tylenol) and other Phenols React as Antioxidants and Destroy Peroxynitrite-based Luminol-dependent Chemiluminescence", Knox Van Dyke et al., J. Biolumin Chemilumin, 1998, pgs. 339-348	
G		"Effect of Nonsteroidal Anti-Inflammatory Drugs on Lipid Peroxidation by Hydroxyl Radical", Yasuhisa Tsujimoto et al., Gen. Pharmac., Vol. 31, No. 3, 1998, pgs. 405-408	
D		"Protection against peroxynitrite dependent tyrosine nitration and $\alpha_1$ -antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline", Matthew Whiteman et al., Annals of the Rheumatic Diseases, No. 55, 1996, pgs. 383-387 (6 Feb. 1996)	
G		"Divergent effects of paracetamol on reactive oxygen intermediate and reactive nitrogen intermediate production by U937 cells", I. Jamil et al., International Journal of Molecular Medicine, No. 4, 1999, pgs 309-312	
G		"Pretreatment of Mice with Macrophage Inactivators Decreases Acetaminophen Hepatotoxicity and the Formation of reactive Oxygen and Nitrogen Species", Sherryl L. Michael, et al., Hepatology, July 1999, pgs. 186-195	
D		"Action of Phenolic Derivatives (Acetaminophen, Salicylate, and 5-Aminosalicylate) as Inhibitors of Membrane Lipid Peroxidation and as Peroxyl Radical Scavengers", Teresa C.P. Dinis et al., Archives of Biochemistry and Biophysics, Vol. 314, No. 1, November 15, 1994, pgs. 161-169	
G		"Effect of Acetaminophen on Oxidative Modification of Human Low Density Lipoprotein", L. Lanningham et al., FASEB Journal, April 1994, Abstract No. 2601	
G		"Paracetamol Catalyzes Myeloperoxidase-Initiated Lipid Oxidation in LDL", S. Kapiotis, Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 17, No. 11, November 1997, pgs. 2855-2860	
G		"Acetaminophen Lowers Fatty Streak Formation and Lipid Oxidation in Hypercholesterolemic Rabbits, Lynette K. Rogers et al., Free Radical Biology & Medicine, November 1999, Abstract No. 337	
G		"Acetaminophen Inhibits Both Chemical And Cell-Mediated Human LDL Oxidation In Vivo and In Vitro", A.A. Taylor et al., Archives of Pharmacology, July 1998, Abstract P 48,5	
G		"Protective Effect of Acetaminophen Against Acute Gastric Mucosal Lesions Induced by Ischemia-Reperfusion in the Rat", Kentaro Nakamoto et al., Pharmacology, 1997, No. 54, pgs. 203-210	
G		"Effect of Acetaminophen on Stress-Induced Gastric Mucosal Lesions in Rats", Hideshi Omura et al., Research Communications in Molecular Pathology and Pharmacology, Vol. 86, No. 3, December 1994, pgs. 297-310	
G		Dorland's Illustrated Medical Dictionary, 25 <sup>th</sup> Edition, W.B. Saunders, 1981, pgs 143 & 154	
G		"Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits", Paul Witting et al., The Journal of Clinical Investigation, Vol. 104, No. 2, July 1999, pgs. 213-220	
G		Dorland's Pocket Medical Dictionary, 21 <sup>st</sup> Edition, 1968, pg. 74	
G		"Acetaminophen", Barbary Armeer et al, Annals of Internal Medicine, Volume 87, No. 2, August 1977, pgs. 202-209	
G		"Paracetamol Inhibits Copper Ion-Induced, Azo Compound-Initiated, and Mononuclear Cell-Mediated Oxidative Modification of LDL", Marit S. Nenseter et al., Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 15, No. 9, September 1995, pgs. 1338-1344	
G		"A Comparison of the Antiatherogenic effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits", Joachim Fruebis et al., 94 J. Clin. Invest. 392-98 (July 1994)	
G		"The Distribution and Chemical Composition of Ultracentrifugally Separated Lipoproteins in Human serum, Richard J. Havel et al., Richard J. Havel et al., 34 J. Clin. Invest., January 1955, pgs. 1345-1353	
G		"Protein Measurement with the Folin Phenol Reagent, Oliver H. Lowry, 193 J. Biol. Chem., May 29, 1951, pgs. 265-275	

Examiner Signature		Date Considered	12/2/02
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

